Fenne Vandervorst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fenne Vandervorst has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Sylvie De Raedt
Department of Neurology (F. Vandervorst, S.D.R.), Universitair Ziekenhuis Brussel, Belgium
4 shared publications Robin Gens
3 shared publications- Alain G. Dupont
Research Centre for Digital Medicine, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium
2 shared publications - Jelle Demeestere
KU Leuven, Leuven Brain Institute, Department of Neurosciences, Experimental Neurology, Belgium (J.D., L.M., A.W.).
2 shared publications - Raul Gomes Nogueira
Department of Neurology and Neurosurgery, UPMC Stroke Institute, University of Pittsburgh School of Medicine, PA
2 shared publications Sebastiaan Engelborghs
Department of Neurology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, Brussels, 1090, Belgium
2 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3292-3305
Beyond the Threshold: Continuous Creatinine Change and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke
BACKGROUND: Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. METHODS: We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. RESULTS: Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07–2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours—well below Kidney Disease: Improving Global Outcomes threshold—was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01–1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13–1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93–0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65–0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. CONCLUSIONS: Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06596603.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3292-3305
Beyond the Threshold: Continuous Creatinine Change and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke
BACKGROUND: Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. METHODS: We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. RESULTS: Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07–2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours—well below Kidney Disease: Improving Global Outcomes threshold—was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01–1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13–1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93–0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65–0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. CONCLUSIONS: Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06596603.
- Open Access
- 20 June 2026
- Published by Elsevier in SSRN Electronic Journal
Utilizing NIHSS subitems to identify patients at risk of post-stroke delirium
Introduction: There are no good post-stroke delirium prediction models. Our aim is to investigate whether certain baseline NIHSS-subitem scores might identify patients at risk of developing post-stroke delirium (PSD), next to well-known risk factors such as age and baseline stroke severity.Methods: In a previously published dataset of 514 patients with acute ischemic stroke, 39% developed PSD within the first week after stroke onset using a retrospective chart review based on DSM-5 criteria. We selected those patients with available NIHSS subitems on admission. Multiple logistic regression analysis and receiver operating characteristics (ROC) analysis were used to identify predictors of PSD.Results: Of the 479 included patients with a median age of 75 (IQR 63-84) and NIHSS of 7 (Interquartile range (IQR) 2-14), 190 (39.7%) developed PSD. Based on multiple logistic regression analysis, age, baseline stroke severity (total NIHSS) and known cognitive dysfunction were associated with PSD. Entering all NIHSS subitems, after collinearity check, showed that scores ≥ 1 on "Level of consciousness (LOC)-commands" (subitem 1c) and on "Facial palsy" (subitem 4) were associated with PSD. Score ≥ 1 on "ataxia” (subitem 7) was associated with a lower risk of PSD. ROC curve analysis of a model including age, pre-stroke mRS and NIHSS subitems 1c, 4 and 7 showed an AUC of 0.83. This was not different from a model containing age, pre-stroke mRS and total NIHSS.Discussion and conclusion: Baseline NIHSS subitem scores, particularly impaired consciousness (1c), facial palsy (4) and ataxia (7), in addition to age and pre-stroke disability, are associated with poststroke delirium. However, incorporating these subitems into a predictive model alongside age and pre-stroke mRS, did not improve its predictive value compared to a model based on age, pre-stroke mRS and total baseline NIHSS score.
- 20 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUtilizing NIHSS subitems to identify patients at risk of post-stroke delirium
Introduction: There are no good post-stroke delirium prediction models. Our aim is to investigate whether certain baseline NIHSS-subitem scores might identify patients at risk of developing post-stroke delirium (PSD), next to well-known risk factors such as age and baseline stroke severity.Methods: In a previously published dataset of 514 patients with acute ischemic stroke, 39% developed PSD within the first week after stroke onset using a retrospective chart review based on DSM-5 criteria. We selected those patients with available NIHSS subitems on admission. Multiple logistic regression analysis and receiver operating characteristics (ROC) analysis were used to identify predictors of PSD.Results: Of the 479 included patients with a median age of 75 (IQR 63-84) and NIHSS of 7 (Interquartile range (IQR) 2-14), 190 (39.7%) developed PSD. Based on multiple logistic regression analysis, age, baseline stroke severity (total NIHSS) and known cognitive dysfunction were associated with PSD. Entering all NIHSS subitems, after collinearity check, showed that scores ≥ 1 on "Level of consciousness (LOC)-commands" (subitem 1c) and on "Facial palsy" (subitem 4) were associated with PSD. Score ≥ 1 on "ataxia” (subitem 7) was associated with a lower risk of PSD. ROC curve analysis of a model including age, pre-stroke mRS and NIHSS subitems 1c, 4 and 7 showed an AUC of 0.83. This was not different from a model containing age, pre-stroke mRS and total NIHSS.Discussion and conclusion: Baseline NIHSS subitem scores, particularly impaired consciousness (1c), facial palsy (4) and ataxia (7), in addition to age and pre-stroke disability, are associated with poststroke delirium. However, incorporating these subitems into a predictive model alongside age and pre-stroke mRS, did not improve its predictive value compared to a model based on age, pre-stroke mRS and total baseline NIHSS score.
- Open Access
- 28 April 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (3)
Quantitative EEG in post-stroke delirium: Spectral and Functional Connectivity Analyses in a Case-Control Study
The online version contains supplementary material available at 10.1007/s12975-026-01413-0.
- 28 April 2026
- Published by Springer Nature in Translational Stroke Research
- Vol. 17 (3)
Open AccessQuantitative EEG in post-stroke delirium: Spectral and Functional Connectivity Analyses in a Case-Control Study
The online version contains supplementary material available at 10.1007/s12975-026-01413-0.
- 8 April 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (1) , 225-239
Interactions Between Direct Oral Anticoagulants and Drugs Involving CYP-Enzymes and P-gp Transporters Detected by a Clinical Decision Support System: A Retrospective Cohort Study
Purpose Physicians can be supported by electronic clinical decision support systems (CDSS) for drug-drug interaction (DDI) management of DDIs between direct oral anticoagulants (DOACs) and CYP3 A4/P-glycoprotein (P-gp) inhibitors and inducers, to prevent adverse drug events (ADEs). Methods A retrospective cohort study was performed studying DDI alerts for DOAC-CYP3 A4/P-gp influencing drug combination prescriptions in patients admitted to a tertiary care hospital. Patient-, DDI-, and ADE-related data were analyzed to explore CDSS performance and real-world DDI management. A multidisciplinary panel conducted an ADE analysis using the Drug Interaction Probability Scale. Results Out of 15,201 triggered CDS alerts, 166 individual alerts were included. Primary indication for DOAC therapy was atrial fibrillation (86.1%). The most involved DOAC was dabigatran (63%). DDI exposure was median 3 days (IQR = 2–7 days). CYP3 A4/P-gp inhibitor DDIs were most prevalent (n = 121), with amiodarone being most prevalently prescribed (71%). Inducers were mainly antiepileptic drugs (n = 31). Thirty-four CDS alerts (20%) were actively shown to the physician upon prescribing (acceptance rate 50%). Eighteen ADEs were identified (11%, 14 bleeding; 4 thromboembolic events), 15 having a possible and 3 a probable probability of being DDI associated. Conclusion Despite a low number of observed, potentially associated ADEs, CDSS for DDI management aids physicians to optimize DOAC treatment as the described DDIs can cause significant patient harm. Increased ADE monitoring and larger real-world studies are needed to refine CDS tools and further optimize patient safety.
- 8 April 2025
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (1) , 225-239
Interactions Between Direct Oral Anticoagulants and Drugs Involving CYP-Enzymes and P-gp Transporters Detected by a Clinical Decision Support System: A Retrospective Cohort Study
Purpose Physicians can be supported by electronic clinical decision support systems (CDSS) for drug-drug interaction (DDI) management of DDIs between direct oral anticoagulants (DOACs) and CYP3 A4/P-glycoprotein (P-gp) inhibitors and inducers, to prevent adverse drug events (ADEs). Methods A retrospective cohort study was performed studying DDI alerts for DOAC-CYP3 A4/P-gp influencing drug combination prescriptions in patients admitted to a tertiary care hospital. Patient-, DDI-, and ADE-related data were analyzed to explore CDSS performance and real-world DDI management. A multidisciplinary panel conducted an ADE analysis using the Drug Interaction Probability Scale. Results Out of 15,201 triggered CDS alerts, 166 individual alerts were included. Primary indication for DOAC therapy was atrial fibrillation (86.1%). The most involved DOAC was dabigatran (63%). DDI exposure was median 3 days (IQR = 2–7 days). CYP3 A4/P-gp inhibitor DDIs were most prevalent (n = 121), with amiodarone being most prevalently prescribed (71%). Inducers were mainly antiepileptic drugs (n = 31). Thirty-four CDS alerts (20%) were actively shown to the physician upon prescribing (acceptance rate 50%). Eighteen ADEs were identified (11%, 14 bleeding; 4 thromboembolic events), 15 having a possible and 3 a probable probability of being DDI associated. Conclusion Despite a low number of observed, potentially associated ADEs, CDSS for DDI management aids physicians to optimize DOAC treatment as the described DDIs can cause significant patient harm. Increased ADE monitoring and larger real-world studies are needed to refine CDS tools and further optimize patient safety.
- 24 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1114-1131
Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention
Direct oral anticoagulants (DOACs) are frequently used for the treatment and prevention of ischaemic stroke in patients with non‐valvular atrial fibrillation. Compared to vitamin K antagonists, DOACs have significant advantages, although their drug–drug interaction (DDI) profile may complicate drug efficacy and safety. This narrative review addresses the clinical challenges posed by these DDIs and the potential pharmacological alternatives and monitoring strategies available.A PubMed search was conducted (1 January 2000–31 December 2023) including human DDI studies on DOAC use and CYP3A4/P‐gp inducers in adult patients, evaluating patient outcome data and recommendations for DDI management.Twenty‐two studies were included. Case reports (n = 6) indicated that antiepileptic drugs such as carbamazepine, phenobarbital and phenytoin may be associated with thromboembolic events. The nested case–control studies (n = 2) and cohort studies (n = 9) found that co‐administration of DOACs and CYP3A4/P‐gp inducers, particularly carbamazepine and phenytoin, increased the risk of thromboembolic events. Pharmacovigilance database analyses indicated a significant association between DOAC DDIs and increased reported stroke rates. Management recommendations in systematic reviews (n = 5) highlighted monitoring when DOACs were combined with inducers. Strategies included using alternative drugs with a weaker or preferentially absent inducing profile. Limited evidence suggests that edoxaban may be an acceptable option in case of DOAC and CYP3A4/P‐gp inducer interactions; however, robust clinical data confirming safety are needed.Present literature indicates a higher thromboembolic risk in patients on DOAC treatment combining CYP3A4‐ and/or P‐gp inducers. DOAC management should be tailored to the individual patient through collaboration between expert healthcare professionals.
- 24 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1114-1131
Prescriptions of CYP3A4‐ and P‐gp inducers for patients on direct oral anticoagulants: Bridging the gap between epidemiology and patient management for optimal thromboembolic event prevention
Direct oral anticoagulants (DOACs) are frequently used for the treatment and prevention of ischaemic stroke in patients with non‐valvular atrial fibrillation. Compared to vitamin K antagonists, DOACs have significant advantages, although their drug–drug interaction (DDI) profile may complicate drug efficacy and safety. This narrative review addresses the clinical challenges posed by these DDIs and the potential pharmacological alternatives and monitoring strategies available.A PubMed search was conducted (1 January 2000–31 December 2023) including human DDI studies on DOAC use and CYP3A4/P‐gp inducers in adult patients, evaluating patient outcome data and recommendations for DDI management.Twenty‐two studies were included. Case reports (n = 6) indicated that antiepileptic drugs such as carbamazepine, phenobarbital and phenytoin may be associated with thromboembolic events. The nested case–control studies (n = 2) and cohort studies (n = 9) found that co‐administration of DOACs and CYP3A4/P‐gp inducers, particularly carbamazepine and phenytoin, increased the risk of thromboembolic events. Pharmacovigilance database analyses indicated a significant association between DOAC DDIs and increased reported stroke rates. Management recommendations in systematic reviews (n = 5) highlighted monitoring when DOACs were combined with inducers. Strategies included using alternative drugs with a weaker or preferentially absent inducing profile. Limited evidence suggests that edoxaban may be an acceptable option in case of DOAC and CYP3A4/P‐gp inducer interactions; however, robust clinical data confirming safety are needed.Present literature indicates a higher thromboembolic risk in patients on DOAC treatment combining CYP3A4‐ and/or P‐gp inducers. DOAC management should be tailored to the individual patient through collaboration between expert healthcare professionals.
- 6 December 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102105
Washout rate of cardiac 123I-meta-iodobenzylguanidine and ischemic stroke outcome
- 6 December 2024
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 45, 102105
Washout rate of cardiac 123I-meta-iodobenzylguanidine and ischemic stroke outcome
- 29 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (3) , 1205-1207
Anti-CASPR2 antibody-associated limbic encephalitis in a patient with a squamous cell carcinoma of the throat
- 29 April 2023
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 123 (3) , 1205-1207
Anti-CASPR2 antibody-associated limbic encephalitis in a patient with a squamous cell carcinoma of the throat
- Open Access
- 19 June 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (5) , 1251-1258
The impact of COVID-19 on acute stroke care in Belgium
A worldwide decline in stroke hospitalizations during the COVID-19 pandemic has been reported. Information on stroke care during the pandemic in Belgium is lacking. This study aims to analyze the impact of COVID-19 on acute stroke care in eight Belgian stroke centers. This Belgian study is part of an international observational and retrospective study in 70 countries and 457 stroke centers. We compared volumes of COVID-19 and stroke hospitalizations, intravenous thrombolysis and endovascular treatment rates, acute treatment time intervals and functional outcome at 90 days during the first wave of the pandemic to two control intervals (March–May 2019 and December–February 2020). From March 2020 to May 2020, 860 stroke patients were hospitalized. In the same time period, 2850 COVID-19 patients were admitted, of which 37 (1.3%) were diagnosed with a stroke. Compared to the months prior to the pandemic and the same time epoch one year earlier, stroke hospitalizations were reduced (relative difference 15.9% [p = 0.03] and 14.5% [p = 0.05], respectively). Despite a reduction in absolute volumes, there was no difference in the monthly proportion of thrombolysis or endovascular treatment provided to the overall stroke hospitalizations. Acute treatment time metrics did not change between COVID-19 pandemic and control time epochs. We found no difference in 90-day functional outcomes nor in mortality after stroke between patients admitted during the pandemic versus control periods. We found a decline in the volume of stroke hospitalizations during the first wave of the COVID-19 pandemic in Belgium. Stroke care quality parameters remained unchanged.
- 19 June 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (5) , 1251-1258
Open AccessThe impact of COVID-19 on acute stroke care in Belgium
A worldwide decline in stroke hospitalizations during the COVID-19 pandemic has been reported. Information on stroke care during the pandemic in Belgium is lacking. This study aims to analyze the impact of COVID-19 on acute stroke care in eight Belgian stroke centers. This Belgian study is part of an international observational and retrospective study in 70 countries and 457 stroke centers. We compared volumes of COVID-19 and stroke hospitalizations, intravenous thrombolysis and endovascular treatment rates, acute treatment time intervals and functional outcome at 90 days during the first wave of the pandemic to two control intervals (March–May 2019 and December–February 2020). From March 2020 to May 2020, 860 stroke patients were hospitalized. In the same time period, 2850 COVID-19 patients were admitted, of which 37 (1.3%) were diagnosed with a stroke. Compared to the months prior to the pandemic and the same time epoch one year earlier, stroke hospitalizations were reduced (relative difference 15.9% [p = 0.03] and 14.5% [p = 0.05], respectively). Despite a reduction in absolute volumes, there was no difference in the monthly proportion of thrombolysis or endovascular treatment provided to the overall stroke hospitalizations. Acute treatment time metrics did not change between COVID-19 pandemic and control time epochs. We found no difference in 90-day functional outcomes nor in mortality after stroke between patients admitted during the pandemic versus control periods. We found a decline in the volume of stroke hospitalizations during the first wave of the COVID-19 pandemic in Belgium. Stroke care quality parameters remained unchanged.
- Open Access
- 30 March 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (1) , e9
Opinions and Beliefs About Telemedicine for Emergency Treatment During Ambulance Transportation and for Chronic Care at Home
Interactive Journal of Medical Research
- 30 March 2016
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 5 (1) , e9
Open AccessOpinions and Beliefs About Telemedicine for Emergency Treatment During Ambulance Transportation and for Chronic Care at Home
Interactive Journal of Medical Research